Health ❯ Healthcare ❯ Pharmaceuticals ❯ Drug Development

Clinical Trials

FDA Warns Novo Nordisk Over Missed Reporting of Serious Semaglutide and GLP-1 Adverse Events

The agency set a 15-business-day deadline for a corrective plan.

Vertex’s IgA Nephropathy Drug Hits Phase 3 Goals, FDA Filing Slated for March

Xenon to Present Topline X-TOLE2 Phase 3 Results in Focal Onset Seizures at 8 A.M. ET Today

CHMP Backs Xolremdi for WHIM Syndrome Under Exceptional Circumstances

Lilly’s Oral GLP-1 Orforglipron Tops Oral Semaglutide in Lancet Phase 3 Diabetes Trial

Novo’s CagriSema Falls Short of Lilly’s Tirzepatide in 84-Week Head‑to‑Head Trial

Novo’s Triple-Hormone Obesity Drug UBT251 Hits 19.7% Mean Weight Loss in China Phase 2

Lilly Combo of Zepbound and Taltz Tops Taltz Alone in Late-Stage Psoriasis Trials

FDA Rejects Disc Medicine’s Bitopertin for EPP After Questioning Surrogate Endpoint

Broad Flu Antibody Nasal Spray Shows Safety and Strong Nasal Neutralization in Phase 1

Pfizer Tops Q4 Estimates but Posts Loss on $4.4 Billion Charge, Reaffirms 2026 Outlook

UK Regulator Flags Rare Pancreatitis, Including Deaths, Tied to Wegovy and Mounjaro

Sanofi’s Venglustat Notches Gaucher Type 3 Phase 3 Win, Misses Fabry Pain Endpoint

AstraZeneca Strikes $1.2 Billion CSPC Pact for Once‑Monthly Obesity and Diabetes Programs

FDA Grants Breakthrough Therapy Designation to Biogen’s Litifilimab for Cutaneous Lupus

Merck Ends Revolution Medicines Takeover Talks After Valuation Standoff

Wegovy Pill Debuts to Strong U.S. Demand as Next‑Gen Obesity Drugs Near Decisions

Sanofi Pushes Amlitelimab Toward 2026 Filings After Mixed Phase 3 Readouts

FDA Delays Two Drugs in National Priority Voucher Program After Safety, Efficacy Flags

Alumis TYK2 Pill Hits Phase 3 Goals in Psoriasis as Stock Jumps and $175 Million Offering Is Planned